These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30807553)

  • 1. PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance.
    Fu Z; Lu C; Zhang C; Qiao B
    Anticancer Drugs; 2019 Aug; 30(7):e0773. PubMed ID: 30807553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells.
    Singh V; Sharma V; Verma V; Pandey D; Yadav SK; Maikhuri JP; Gupta G
    Eur J Nutr; 2015 Dec; 54(8):1255-67. PubMed ID: 25408199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line.
    Kanbur E; Baykal AT; Yerlikaya A
    Med Oncol; 2021 Aug; 38(9):112. PubMed ID: 34363546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor.
    Kuroda K; Liu H
    Int J Oncol; 2019 Apr; 54(4):1357-1366. PubMed ID: 30720063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSMA5 contributes to progression of lung adenocarcinoma in association with the JAK/STAT pathway.
    Lu F; Zhou J; Chen Q; Zhu J; Zheng X; Fang N; Qiao L
    Carcinogenesis; 2022 Aug; 43(7):624-634. PubMed ID: 35605971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance.
    Wu YX; Yang JH; Saitsu H
    Oncotarget; 2016 Nov; 7(47):77622-77634. PubMed ID: 27769058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
    Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
    J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
    Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
    Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.
    Zhao SG; Jackson WC; Kothari V; Schipper MJ; Erho N; Evans JR; Speers C; Hamstra DA; Niknafs YS; Nguyen PL; Schaeffer EM; Ross AE; Den RB; Klein EA; Jenkins RB; Davicioni E; Feng FY
    Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):229-36. PubMed ID: 25986914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.
    Zafeiropoulou K; Kalampounias G; Alexis S; Anastasopoulos D; Symeonidis A; Katsoris P
    PLoS One; 2024; 19(2):e0289904. PubMed ID: 38412186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition on Proteasome β1 Subunit Might Contribute to the Anti-Cancer Effects of Fangchinoline in Human Prostate Cancer Cells.
    Li D; Lu Y; Sun P; Feng LX; Liu M; Hu LH; Wu WY; Jiang BH; Yang M; Qu XB; Guo DA; Liu X
    PLoS One; 2015; 10(10):e0141681. PubMed ID: 26512898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
    Thangavadivel S; Zelle-Rieser C; Olivier A; Postert B; Untergasser G; Kern J; Brunner A; Gunsilius E; Biedermann R; Hajek R; Pour L; Willenbacher W; Greil R; Jöhrer K
    Oncotarget; 2016 Nov; 7(48):78605-78618. PubMed ID: 27732933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (Immuno)proteasomes as therapeutic target in acute leukemia.
    Cloos J; Roeten MS; Franke NE; van Meerloo J; Zweegman S; Kaspers GJ; Jansen G
    Cancer Metastasis Rev; 2017 Dec; 36(4):599-615. PubMed ID: 29071527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sea cucumber extract TBL-12 inhibits the proliferation, migration, and invasion of human prostate cancer cells through the p38 mitogen-activated protein kinase and intrinsic caspase apoptosis pathway.
    Yuan L; Huang X; Zhou K; Zhu X; Huang B; Qiu S; Cao K; Xu L
    Prostate; 2019 Jun; 79(8):826-839. PubMed ID: 30889629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
    Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 18. Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells.
    Wei W; Li H; Zhang G; Zhang Y; Wu K; Bao R; Wang G; Zheng H; Xia Y; Li C
    Med Oncol; 2020 Nov; 37(12):116. PubMed ID: 33215275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
    Zhang XD; Baladandayuthapani V; Lin H; Mulligan G; Li B; Esseltine DW; Qi L; Xu J; Hunziker W; Barlogie B; Usmani SZ; Zhang Q; Crowley J; Hoering A; Shah JJ; Weber DM; Manasanch EE; Thomas SK; Li BZ; Wang HH; Zhang J; Kuiatse I; Tang JL; Wang H; He J; Yang J; Milan E; Cenci S; Ma WC; Wang ZQ; Davis RE; Yang L; Orlowski RZ
    Cancer Cell; 2016 May; 29(5):639-652. PubMed ID: 27132469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-498 promotes proliferation, migration, and invasion of prostate cancer cells and decreases radiation sensitivity by targeting PTEN.
    Duan XM; Liu XN; Li YX; Cao YQ; Silayiding A; Zhang RK; Wang JP
    Kaohsiung J Med Sci; 2019 Nov; 35(11):659-671. PubMed ID: 31332950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.